“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

Receptors can display different ligand binding properties depending on whether or not they are engaged in a receptor heteromer. The D 1-D 2 receptor heteromer provides an example of changes in ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

Early in situ hybridization studies indicated that NOS interneurons contain low levels of dopamine (DA) D 1-like receptor mRNA (Le Moine et al, 1991). Moreover, recent double-labeling ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

• Fenoldopam (a medicine that rapidly widens and relaxes blood vessels) probably reduces the risk of developing acute kidney injury (AKI) (a condition where the kidneys suddenly lose their ability to ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...

The drug is a partial agonist that selectively targets dopamine D1/D5 receptor subtypes. Also in phase 2, the company has CVL ...